7,633.75

+19.75

+0.26%

52,024.00

+106.00

+0.20%

28,653.25

+119.25

+0.42%

Russell 2000 Futures

2,829.90

+8.60

+0.30%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,903.70

+4.80

+0.12%

77,971.25

+547.27

+0.71%

Crude Oil Dec 26

102.31

-1.81

-1.74%

US Private Equity

10,850.63

-82.20

-0.75%

XETRA - Delayed Quote EUR

Johnson & Johnson (JNJ.DE)

246.70 +0.75 (+0.30%)

At close: October 30 at 5:35:42 PM GMT+1

Loading Chart for JNJ.DE

Chart Range Bar

Interval:

In partnership with ChartIQ

5 Most Undervalued Dividend Growth Stocks According to Hedge Funds

5 Most Undervalued Dividend Growth Stocks According to Hedge Funds

4 Blue-Chip Dividend Stocks That Kept Raising Payouts Through 2008 and 2020

4 Blue-Chip Dividend Stocks That Kept Raising Payouts Through 2008 and 2020

Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

Suze Orman Says You Don’t Have to Buy Every Market Dip. Here’s Why

Suze Orman Says You Don’t Have to Buy Every Market Dip. Here’s Why

Roth IRA vs. Taxable Account: How Much of $17,985 in Blue-Chip Dividends Would You Keep?

Roth IRA vs. Taxable Account: How Much of $17,985 in Blue-Chip Dividends Would You Keep?

If a Bear Market Is Coming, History Says These Stocks Could Be the Smartest to Own

If a Bear Market Is Coming, History Says These Stocks Could Be the Smartest to Own

5 Dividend Stocks to Buy and Hold for the Next 5 Years

5 Dividend Stocks to Buy and Hold for the Next 5 Years

3 Biotech Stocks With Upside Of Up To 80%

3 Biotech Stocks With Upside Of Up To 80%

Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.

Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.

Stryker Sinks 5% on Q3 Miss and Guidance Cut: “Fall Short of Our Expectations”

Stryker Sinks 5% on Q3 Miss and Guidance Cut: “Fall Short of Our Expectations”

How Investors Are Reacting To Johnson & Johnson Stock New Drug Progress

How Investors Are Reacting To Johnson & Johnson Stock New Drug Progress

Mobilize your Website

View Site in Mobile | Classic

Share by: